S1 Biopharma

S1 Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on treating male and female sexual dysfunction. The company’s development programs include first-in-class non-hormonal therapies designed to treat hypoactive sexual desire disorder by restoring the natural balance of key neurotransmitters in the brain. The company’s lead candidate product, Lorexys, is currently being prepared to advance into a Phase 2b clinical trial for Hypoactive Sexual Desire Disorder (HSDD) in women. S1 Biopharma is evaluating partnerships, collaborations, and out-licensing agreements that would enable the company to rapidly advance its sexual dysfunction franchise and accelerate the commercialization of its drug candidates in the United States and internationally.